28 Primary and secondary liver malignancies

Primary and secondary liver malignancies

15

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 15/07/2022

15. REFERENCES

19. Joo I, Kim SY, Kang TW, Kim YK, Park BJ, Lee YJ et al. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study. Radiology 2020;296(2):335–45. https://doi.org/10.1148/radiol.2020192275. 20. Muntaser Saied Ahmad, Nursakinah Suardi, Ahmad Shukri, Nik Noor Ashikin Nik Ab Razak, Ammar A. Oglat, Hjouj Mohammad. A Recent Short Review in Non-Invasive Magnetic Resonance Imaging on Assessment of HCC Stages: MRI Findings and Pathological Diagnosis. Journal of Gastroenterology and Hepatology Research 2020;9(2):3113–23. 21. Renzulli M, Biselli M, Brocchi S, Granito A, Vasuri F, Tovoli F et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high- grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 2018;67(9):1674–82. https://doi.org/10.1136/ gutjnl-2017-315384. 22. Rühl R, Seidensticker M, Peters N, Mohnike K, Bornschein J, Schütte K et al. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT- guided high-dose-rate brachytherapy. Digestive diseases (Basel, Switzerland) 2009;27(2):189–99. https://doi.org/10.1159/000218352. 23. Davidson JC, Rahim S, Hanks SE, Patel IJ, Tam AL, Walker TG et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part I: Review of Anticoagulation Agents and Clinical Considerations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. Journal of Vascular and Interventional Radiology 2019;30(8):1155–67. https://doi.org/10.1016/j.jvir.2019.04.016. 24. Patel IJ, Rahim S, Davidson JC, Hanks SE, Tam AL, Walker TG et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the CanadianAssociation for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. Journal of Vascular and Interventional Radiology 2019;30(8):1168-1184.e1. https://doi.org/10.1016/j. jvir.2019.04.017. 25. ChehabMA, Thakor AS, Tulin-Silver S, Connolly BL, Cahill AM, Ward TJ et al. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. Journal of Vascular and Interventional Radiology 2018;29(11):1483-1501.e2. https://doi.org/10.1016/j. jvir.2018.06.007. 26. Mohnike K, Sauerland H, Seidensticker M, Hass P, Kropf S, Seidensticker R et al. Haemorrhagic Complications and Symptomatic VenousThromboembolism in Interventional Tumour Ablations:The Impact of Peri-interventionalThrombosis Prophylaxis. CardioVascular and Interventional Radiology 2016;39(12):1716–21. https://doi.org/10.1007/s00270-016-1423-1. 27. Mohnike K, Wolf S, Damm R, Seidensticker M, Seidensticker R, Fischbach F et al. Radioablation von Lebermalignomen mit interstitieller High-dose- rate-Brachytherapie Komplikationen und Risikofaktoren. Strahlenther Onkol 2016;192(5):288–96. https://doi.org/10.1007/s00066-016-0957-0. 28. Wieners G, Schippers AC, Collettini F, Schnapauff D, Hamm B, Wust P et al. CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer. Hepatobiliary & pancreatic diseases international HBPD INT 2015;14(5):530–8. https://doi.org/10.1016/ s1499-3872(15)60409-x. 29. Bolondi L, Burroughs A, Dufour J-F, Galle PR, Mazzaferro V, Piscaglia F et al. Heterogeneity of patients with intermediate (BCLCB) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Seminars in liver disease 2012;32(4):348–59. https://doi.org/10.1055/s-0032-1329906. 30. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. The Lancet 2012;379(9822):1245–55. https://doi.org/10.1016/S0140-6736(11)61347-0. 31. Crocetti L, Baere T de, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. CardioVascular and Interventional Radiology 2010;33(1):11–7. https://doi.org/10.1007/s00270-009-9736-y. 32. Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med 2018;16(1):113. https://doi.org/10.1186/s12916-018-1110-y.

1. Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives. J Contemp Brachytherapy 2016;8(3):251–61. https://doi. org/10.5114/jcb.2016.61068. 2. Walter F, Nierer L, Rottler M, Duque AS, Weingandt H, Well J et al. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. Radiat Oncol 2021;16(1):86. https:// doi.org/10.1186/s13014-021-01812-7. 3. Böning G, Büttner L, Jonczyk M, Lüdemann WM, Denecke T, Schnapauff D et al. Complications of Computed Tomography-Guided High-Dose-Rate Brachytherapy (CT-HDRBT) and Risk Factors: Results fromMore than 10 Years of Experience. CardioVascular and Interventional Radiology 2020;43(2):284–94. https://doi.org/10.1007/s00270-019-02386-4. 4. Hass P, Mohnike K, Kropf S, Brunner TB, Walke M, Albers D et al. Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. Brachytherapy 2019;18(6):823–8. https:// doi.org/10.1016/j.brachy.2019.08.003. 5. Couinaud C. Anatomie chirurgicale du foie. Quelques aspects nouveaux. Chirurgie; memoires de l'Academie de chirurgie 1986;112(5):337–42. 6. Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Annals of surgery 2013;257(3):377–82. https:// doi.org/10.1097/SLA.0b013e31825a01f6. 7. Toni ENde, Schlesinger-Raab A, FuchsM, ScheppW, Ehmer U, Geisler F et al. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut 2020;69(1):168–76. https://doi.org/10.1136/gutjnl-2018-318193. 8. Global Cancer Observatory. [October 20, 2021]; Available from: https://gco. iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. 9. Hepatocellular carcinoma overview. [October 22, 2021]; Available from: https:// www.pathologyoutlines.com/topic/livertumorHCC.html. 10. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature reviews. Gastroenterology & hepatology 2019;16(10):589–604. https:// doi.org/10.1038/s41575-019-0186-y. 11. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, ArnoldD. Biliary cancer: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2016;27(suppl 5):v28-v37. https://doi.org/10.1093/annonc/mdw324. 12. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. CLEP 2014;6:99–109. https://doi.org/10.2147/CLEP.S37357. 13. Ghouri YA, Mian I, Blechacz B. Cancer review: Cholangiocarcinoma. Journal of Carcinogenesis 2015;14(1):1. https://doi.org/10.4103/1477-3163.151940. 14. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nature reviews. Clinical oncology 2018;15(2):95–111. https://doi.org/10.1038/nrclinonc.2017.157. 15. Hellman S, WeichselbaumRR. Oligometastases. JCO 1995;13(1):8–10. https:// doi.org/10.1200/JCO.1995.13.1.8. 16. Lievens Y, GuckenbergerM, Gomez D, HoyerM, Iyengar P, Kindts I et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO- ASTRO consensus document. Radiotherapy and Oncology 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003. 17. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy andOncology and EuropeanOrganisation for Research and Treatment of Cancer consensus recommendation. The Lancet Oncology 2020;21(1):e18-e28. https://doi.org/10.1016/S1470-2045(19)30718-1. 18. Wybranski C, Siedek F, Damm R, Gazis A, Wenzel O, Haneder S et al. Respiratory motion artefacts in Gd-EOB-DTPA (Primovist/Eovist) and Gd- DOTA (Dotarem)-enhanced dynamic phase liver MRI after intensified and standard pre-scan patient preparation: A bi-institutional analysis. PLOS ONE 2020;15(3):e0230024. https://doi.org/10.1371/journal.pone.0230024.